Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Prothena

NASDAQ PRTA
$22.39 1.71 7.64%
Today share price
Ireland
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 21 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

1.20B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
583.59M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.45
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
53.71M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-38.39 %

Upcoming events Prothena

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Prothena

Stock analysis Prothena

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-6.98 28.42
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
2.14 4.33
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-2.78 9.95
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
2.95 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-34.32 7.67

Price change Prothena per year

10.66$ 79.75$
Min Max

Summary analysis Prothena

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Prothena

Revenue and net income Prothena

All parameters

Stock news Prothena

All news
8 January в 21:45

Prothena Shares Down 19% After Drug Updates

8 January в 21:45

Prothena Shares Down 19% After Drug Updates

22 November 2022 в 00:35

Prothena Achieves $40M Clinical Milestone Payment From Novo Nordisk

22 November 2022 в 00:30

Prothena Achieves $40M Clinical Milestone Payment From Novo Nordisk

26 April 2022 в 20:25

Prothena Shares Reverse Early Gains, Drop 10%

26 April 2022 в 20:25

Prothena Shares Reverse Early Gains, Drop 10%

26 April 2022 в 16:00

Prothena Gets Fast Track Designation for PRX012 Alzheimer's Treatment

26 April 2022 в 16:00

Prothena Gets Fast Track Designation for PRX012 Alzheimer's Treatment

1 October 2021 в 23:55

Prothena Names CFO to Additional Role of Chief Strategy Officer

1 October 2021 в 23:55

Prothena Names CFO to Additional Role of Chief Strategy Officer

12 July 2021 в 17:29

Prothena sells amyloidosis portfolio to Novo Nordisk for up to $1.2 billion

12 July 2021 в 17:14

Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 bln

1 June 2021 в 12:40

Санкт-Петербургская биржа допустит к торгам акции Prothena, Skillz и Vimeo

About company Prothena

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Address:
77 Sir John Rogerson?s Quay, Dublin, Ireland, 2
Company name: Prothena
Issuer ticker: PRTA
ISIN: IE00B91XRN20
Country: Ireland
Exchange: NASDAQ
Currency: $
IPO date: 2012-12-21
Sector: Healthcare
Industry: Biotechnology
Site: https://www.prothena.com

On which stock exchange are Prothena (PRTA) stocks traded?

Prothena (PRTA) stocks are traded on NASDAQ.

What is the ticker of Prothena stocks (PRTA)?

The stock ticker of Prothena’s stocks or in other words, the code is PRTA. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Prothena (PRTA) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Prothena (PRTA) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Prothena (PRTA) stocks traded?

Prothena (PRTA) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Prothena (PRTA) stocks today?

The current price of Prothena stocks on 16.05.2024 is 22.39 dollars. per share.

What is the dynamics of Prothena (PRTA) stocks from the beginning of the year?

Prothena (PRTA) quotes have increased by -41.9% from the beginning of the year up to 22.39 dollars. per 1 stocks.

How much did Prothena (PRTA) stocks increase in мае 2024?

This month Prothena (PRTA) quotes have increased by 4.53% to 22.39 dollars. per share.

How much are Prothena (PRTA) stocks worth?

Today, on October, 16.05.2024 Prothena’s (PRTA) stocks cost 22.39 dollars..

What is the market capitalization of Prothena (PRTA)?

Capitalization is the market value of Prothena (PRTA) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 16.05.2024, the market capitalization of Prothena (PRTA) is estimated at about 1202656460 dollars.